Delivery Order SPE2DE21D0007-SPE2D625F6FA8
- Not listed
- Ortho-Clinical Diagnostics, Inc., headquartered in Raritan, New Jersey, was awarded a delivery order valued at $1,910.02 on August 6, 2025, for Anti-A Bioclone 15x10ml medical diagnostic reagents. The contract, which will be completed by August 27, 2025, was issued without a set-aside designation, indicating open competition. The funding originates from the Medical Supply Chain within the Department of Defense, with the place of performance located in Raritan, New Jersey. This delivery order...
- Ortho-Clinical Diagnostics, Inc. was awarded a delivery order valued at $1,871.28 for Anti-A Bioclone 15x10ml on July 21, 2025, with an ultimate completion date of July 24, 2025. The contract utilizes fixed-price pricing with economic price adjustment and was awarded without a set-aside designation, indicating open competition. The work will be performed in Raritan, New Jersey, and is funded by the Defense Health Agency's Medical Supply Chain, which supports critical medical diagnostic...
- The U.S. Defense Department's Medical Supply Chain agency awarded a delivery order valued at $1,109.97 to Ortho-Clinical Diagnostics, Inc. for Anti-B Bioclone 15x10ML on August 11, 2025, with completion targeted for August 14, 2025. The contract utilizes fixed-price pricing with economic price adjustment and carries no set-aside designation, indicating open competition. Ortho-Clinical Diagnostics, headquartered in Raritan, New Jersey, is a for-profit medical equipment manufacturer specializing...
- Ortho-Clinical Diagnostics, Inc. has been awarded a delivery order contract by the Defense Medical Supply Chain with a ceiling value of $1,767.32 for Rght Anti-A B Bcln 10ml Btl Orth Bb—a specialized blood bank diagnostic reagent. The contract award is dated July 18, 2025, with an ultimate completion date of July 30, 2025, and will be performed at the company's facility in Raritan, New Jersey. This delivery order employs fixed-price contracting with economic price adjustment and was awarded...
- Ortho-Clinical Diagnostics, Inc. was awarded a $1,156.61 fixed-price delivery order by the Defense Medical Supply Chain on July 14, 2025, for the supply of Anti-A Bioclone 15x10ml reagent products. The contract is scheduled for ultimate completion by August 4, 2025, and will be performed at the company's facility in Raritan, New Jersey. No small business set-aside designation was utilized for this award, indicating open competition among qualified vendors. This delivery order represents a...
- The U.S. Department of Defense Medical Supply Chain awarded a delivery order valued at $1,037.23 to Ortho-Clinical Diagnostics, Inc. for Reagent Anti-D Bioclone 150ML Monoclonal on September 3, 2025. The contract employs firm fixed-price pricing with no set-aside designation, indicating open competition. The award will be performed at the contractor's facility in Raritan, New Jersey, with an ultimate completion date of September 8, 2025. Ortho-Clinical Diagnostics, Inc., a for-profit medical...
- Ortho-Clinical Diagnostics, Inc. was awarded a delivery order contract on September 5, 2025, by the Defense Medical Supply Chain for the supply of Reagent Anti-D Bioclone 150mL Monoclonal with a ceiling value of $1,037.23. This is a firm fixed-price delivery order with an ultimate completion date of September 10, 2025, and will be performed at the company's facility in Raritan, New Jersey. No set-aside designation was used for this award, indicating it was competed openly. The contract...
- The U.S. Defense Department's Medical Supply Chain awarded a delivery order valued at $1,109.97 to Ortho-Clinical Diagnostics, Inc. for Anti-A Bioclone 15x10ML on August 1, 2025, with an ultimate completion date of August 6, 2025. The contract utilizes fixed-price pricing with economic price adjustment and carries no set-aside designation, indicating open competition. Performance will occur at the contractor's facility in Raritan, New Jersey. Ortho-Clinical Diagnostics, Inc., a for-profit...
- Ortho-Clinical Diagnostics, Inc., headquartered in Raritan, New Jersey, was awarded a delivery order valued at $5,532.10 by the Defense Health Agency's Medical Supply Chain on September 26, 2025, for a RGT Anti-D BCLN 150ML MNCLN ABO GRP BB product. This fixed-price delivery order with economic price adjustment carries an ultimate completion date of October 1, 2025, and will be performed in Raritan, New Jersey. The award was made without a set-aside designation, indicating open competition among...
- Ortho-Clinical Diagnostics, Inc., headquartered in Raritan, New Jersey, was awarded a delivery order valued at $1,963.68 by the Defense Medical Supply Chain on August 5, 2025, for Rgt Anti-A B Bcln 10mL bottles used in orthopedic blood bank applications. The contract is structured as a firm fixed-price delivery order with no set-aside designation, indicating open competition, and carries an ultimate completion date of August 8, 2025. Performance will be conducted at the awardee's facility in...
- SPE2DE21D0007Indefinite Delivery Contract
- SPE2DE21D0007-SPE2D625F6FA8Delivery Order
Ortho-Clinical Diagnostics, Inc. was awarded a delivery order contract on July 11, 2025, by the Medical Supply Chain division of the Department of Defense for the supply of Anti-A Bioclone 15x10ml reagents, valued at $1,156.61. The contract employs fixed-price pricing with economic price adjustment provisions and is scheduled for ultimate completion by August 1, 2025. The work will be performed at the company's facility in Raritan, New Jersey. No set-aside designation was used in this procurement, indicating the contract was competitively awarded. Ortho-Clinical Diagnostics, Inc., headquartered in Raritan, New Jersey, is a for-profit medical equipment manufacturer and self-certified HUBZone joint venture specializing in diagnostic solutions for federal healthcare agencies. The company has established a substantial federal contracting presence, particularly with the Department of Veterans Affairs, Indian Health Service, Defense Health Agency, and National Institutes of Health, primarily through blanket purchase agreements and delivery orders under GSA Schedule contracts. This delivery order for diagnostic reagents supports the company's role in providing critical laboratory testing infrastructure and consumables to federal defense healthcare operations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.2k | 7/11/25 |